APT: Assessing PA-824 for Tuberculosis

Location

Cape Town, South Africa

Dates

01/18/2038 - 01/18/2038

PI

Kelly Dooley, MD, PhD

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in partnership with UCT Lung Institute

Projects

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

Enhancing models of HIV,viral hepatitis,...

The goal of this five-year project is to assist the United States Centers for Disease Control and Prevention in their approach...

Read More

Impact of diabetes on TB treatment outcomes...

This is a study to prospectively enroll and follow TB patients co-infected with diabetes and TB patients without diabetes...

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More